What Нитроксолин-УБФ Treats: Main Uses and Benefits

This medication is commonly used to address acute, disruptive symptoms stemming from infections of the urogenital system. It is classified as a urinary antibacterial and anti-infective agent. The medication is applied to address susceptible pathogens in the urinary tract, which helps ease distressing manifestations like painful urination (dysuria) and a frequent, persistent urge to void, contributing to improved comfort and supporting functional stability during symptomatic periods.

The medication is relevant for managing infections of the lower and upper urinary tract, including cystitis, urethritis, and pyelonephritis, as well as inflammatory conditions of the male genital organs like prostatitis and epididymitis. It is also an important therapeutic option for long-term prophylaxis to help manage the recurrence of chronic infections.

“The primary goal of using this medication is to support the patient during difficult episodes by easing distress and managing the burden of infectious symptoms.”

---

Quick Fact: Relief for Urogenital Discomfort

Domain Focus	Key Clinical Scenario	Therapeutic Benefit
Acute Infections	Uncomplicated Cystitis, Urethritis	Helps ease painful and urgent symptoms.
Complex Conditions	Pyelonephritis, Prostatitis	Supports the management of deep-seated inflammation.
Recurrence Risk	Long-term Prophylaxis	Supports management of symptom recurrence.

Who can and cannot use Нитроксолин-УБФ?

The official eligibility profile for Nitroxoline (Нитроксолин-УБФ) defines strict criteria for use based on patient health status and age. The medicine is designated for use by adults, adolescents, and children who meet the minimum age requirement and possess no stated contraindications.

Populations for Whom Use is Contraindicated

Use of this medicine is absolutely prohibited for specific populations and conditions as mandated by regulatory documents:

• Hypersensitivity: Patients with known allergy to Nitroxoline or to any related 8-hydroxyquinoline derivatives (quinolines).
• Organ Function: Individuals with severe hepatic diseases or severe renal function disorders, including conditions characterized by oliguria (low urine output) or anuria (no urine output).
• Metabolic/Neurological: Patients with Deficiency of Glucose-6-Phosphate Dehydrogenase (G6PD) or pre-existing nervous system diseases such as neuritis, polyneuritis, or cataracts.

Age and Life Stage Restrictions

Life Stage	Eligibility Status	Regulatory Basis
Pediatric	Contraindicated in infants and in children under four years of age.	Absolute restriction based on developmental considerations.
Geriatric	Use with caution is advised due to the potential for drug cumulation in the elderly.	Conditional use/cautionary restriction.
Reproductive	Contraindicated during both Pregnancy and Lactation (Breastfeeding).	Explicit absolute prohibition.

The official regulatory profile for Nitroxoline (the active ingredient in Нитроксолин-УБФ) defines interactions primarily based on a single pharmacokinetic constraint. The profile lacks documented interactions for many common pathways, such as metabolic enzyme systems or drug transporters.

---

Exposure Modification by Mineral Salts

Co-administration with preparations containing multivalent cations, specifically certain Magnesium preparations and other mineral salts, leads to a clinically significant interaction. This pattern is documented as the impairment of Nitroxoline absorption, which results in reduced systemic exposure and lower drug levels. This reduction necessitates a specific procedural constraint in the administration schedule.

---

Mandatory Administration Timing

To prevent the reduction in bioavailability, official labeling requires a mandatory separation in the administration schedule for the interacting multivalent cation product. The mineral preparation must be administered 3 to 4 hours before or after the dose of Nitroxoline. This timing rule is the primary restriction noted in the official interaction context, serving as a procedural solution to the absorption-based interaction.

---

Absence of Documented Interactions

Verified regulatory documents do not list formal contraindications based on interaction risk. Furthermore, there are no official statements detailing interactions related to cytochrome P450 (CYP) enzymes, drug transporters, or specific pharmacodynamic effects. No specific warnings are documented for interactions with alcohol, food, or herbal products, nor are there population-specific interaction cautions noted in the official labeling.

1. Molecular Action: Metal-Ion Chelation and Starvation

The drug's activity is initiated by its chemical structure, which allows it to function as a chelator, capturing and sequestering essential divalent metal cations, primarily Zinc (Zn^2+) and Iron (Fe^2+/Fe^3+), required by pathogenic microbes. This fundamental chemical sequestration creates a state of biological starvation by disrupting microbial metal homeostasis, resulting in the systemic control of microbial proliferation and viability.

2. Pathway Effect: Inactivation of Key Microbial Enzymes

The resulting metal depletion causes the functional inactivation of numerous metal-dependent microbial enzymes, notably Ribonucleotide Reductase (RNR), which is essential for synthesizing DNA building blocks. This halt in the nucleic acid synthesis pathway prevents the pathogen from replicating, leading directly to the exhibition of both a bactericidal (cell-killing) and bacteriostatic (growth-halting) mechanistic consequence.

3. Structural Impact: Disrupting Biofilms and Resistance

The chelating mechanism also extends to the structural components of microbial communities by interfering with metal ions used to stabilize the biofilm matrix. Furthermore, it functionally disables key Metallo-beta-Lactamases, which are resistance enzymes, contributing to the suppression of established microbial defense systems via enzyme inhibition and assisting in the systemic disruption and reduction of entrenched microbial populations.

How to Use Нитроксолин-УБФ: Administration Guidelines

Administration and Dosage

The approved route for administering this medication is oral (by mouth), utilizing the 250 mg Nitroxoline tablet formulation. The dosing schedule defines the amount and frequency of intake for standard use.

Indication Focus	Single Dose	Frequency	Total Daily Dose
Acute Infection Treatment	250 mg	3 times per day (t.i.d.)	750 mg

Procedural Instructions and Course Duration

For the treatment of acute infections, the dose of 250 mg is typically taken every 8 hours, resulting in the maximum standard daily dose of 750 mg. To optimize absorption and gastric tolerance, the tablet is generally recommended to be taken with or immediately after a meal.

The standard duration for an acute treatment course ranges from 5 to 10 days. For long-term prophylaxis to manage recurrence, the medication may be used over an extended period at a lower, often once-daily dose.

Population-Specific Use Rules

Instructions require caution and modification for specific patient groups:

• Renal Impairment: Use is contraindicated in patients with severe renal failure, and clinical monitoring is required for non-severe impairment, as the drug is renally excreted.
• Pediatric Use: Dosing must be carefully adjusted based on the child's age or weight and is advised under specialist supervision.

Recent Clinical Evidence for Nitroxoline

Nitroxoline is an older antimicrobial agent that has been used historically for the treatment and prophylaxis of uncomplicated urinary tract infections (uUTIs). While the drug has a long history of clinical use in some European and Asian countries, recent research interest has focused on its activity against drug-resistant pathogens and its potential for drug repurposing.

Evidence in Urinary Tract Infections (UTIs)

• General Efficacy: A number of clinical studies, including older trials and meta-analyses, have generally shown that nitroxoline is associated with comparable microbiological eradication rates in women with uncomplicated lower UTIs when compared to certain other antimicrobials. However, the quality of some older trials may not fully align with modern scientific standards, leading to calls for more well-structured, contemporary randomized clinical trials.
• Activity against Resistance: Modern laboratory (in vitro) studies have indicated that nitroxoline retains activity against certain strains of uropathogens, such as Escherichia coli, which have developed multidrug resistance (MDR) to commonly used antibiotics. This finding supports the drug's consideration in regions with high local resistance patterns.

Emerging Research Areas

The unique mechanism of action of nitroxoline, which involves the chelation of metal ions, has led to its investigation beyond its established use in UTIs:

• Anti-biofilm Properties: Research suggests nitroxoline may affect the formation of bacterial biofilms, which are associated with persistent and catheter-related infections.
• Anticancer Potential: Preclinical studies, primarily in cell lines and animal models, have demonstrated that nitroxoline can inhibit processes involved in tumor growth, such as angiogenesis (new blood vessel formation). This has led to the initiation of early-phase clinical trials in some regions to investigate its potential role as an anti-angiogenic agent, particularly in urological cancers.

Key Studies & References

1. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer – a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2

Common questions about Нитроксолин-УБФ (FAQ)

Q: Can Нитроксолин-УБФ be used for infections outside of the urinary system?

Official regulatory documents state that the primary approved use (indication) for this medicine is the treatment of bacterial infections, especially those affecting the urinary tract. The official labeling does not define or list any other specific approved uses for different parts of the body.

Q: What kind of bacteria or microorganisms is Нитроксолин-УБФ designed to target?

According to official product information, this drug is described as demonstrating activity against a variety of microbial organisms, including both Gram-positive and Gram-negative bacteria. It is sometimes described as having a broader spectrum that also includes certain fungal species.

Q: How long do temporary side effects from Нитроксолин-УБФ typically persist?

Regulatory safety information notes that certain common temporary side effects, such as mild stomach discomfort or nausea, are often reported to be more frequent at the very beginning of the treatment period. This suggests that these particular effects may subside as the course of medicine continues.

Q: Does Нитроксолин-УБФ cause increased sensitivity to sunlight (photosensitivity)?

Official regulatory safety information does not commonly list increased sensitivity to sunlight (photosensitivity) as a known adverse reaction associated with this medicine. If a user has specific concerns about sun exposure during treatment, they should discuss this with a healthcare professional.

Q: Does the medicine have any described impact on a person's ability to drive or safely operate machinery?

Official labeling documents state that this medicine generally has no or negligible influence on a person’s ability to drive vehicles or safely operate machinery. If any side effects occur that could potentially impair alertness, such as headaches, caution is advised.

Q: What information is available regarding the risk of rare but severe skin reactions linked to Нитроксолин-УБФ?

Official documents note that allergic skin reactions, such as a rash, are uncommon events associated with this medicine. It is essential to understand that a known allergy or hypersensitivity to the drug is listed as a contraindication, which means the medicine should not be used in such cases.

Q: Does having a chronic condition such as diabetes mellitus affect eligibility to take Нитроксолин-УБФ?

According to official regulatory documents, having diabetes mellitus is not listed as a specific contraindication (a reason to absolutely avoid use) or a special precaution for using this medicine. Contraindications are usually reserved for conditions like severe liver or kidney problems.

Q: What is the average period that the active substance of Нитроксолин-УБФ remains detectable in the body?

Pharmacokinetic data, which describes how the drug moves through the body, indicates that the active substance is rapidly absorbed and typically reaches its highest level in the bloodstream within a few hours. The substance is then continually processed and gradually eliminated from the body.

Q: How does the body typically process and eliminate (metabolize and excrete) Нитроксолин-УБФ?

The body processes this medicine primarily in two ways: it is subjected to metabolism (chemical breakdown) within the liver and is then mainly eliminated from the body through the kidneys (renal excretion). The fact that the medicine is mainly eliminated through the kidneys is noted in official documentation.

Q: Have any significant or recent large-scale clinical trials been conducted on this drug that are widely cited?

Regulatory summaries and official information often reference older clinical trials that established the efficacy of the drug, particularly for uncomplicated urinary tract infections. More contemporary research has focused on the drug’s potential against resistant bacteria and its novel mechanism of action.

Q: What is the generally expected shelf life of Нитроксолин-УБФ tablets?

The official shelf life for the tablets is determined by the manufacturer’s stability data and is always clearly printed as the expiration date on the original packaging and container label. The product should not be used past this expiration date.

Q: Can the administration of Нитроксолин-УБФ potentially interfere with the results of certain common laboratory tests?

Official labeling does not typically include specific warnings stating that this medicine interferes with the results of common laboratory tests. Informing medical staff of all current medications before laboratory testing is a general medical consideration.

Q: How is the role and safety profile of Нитроксолин-УБФ explained in official, patient-facing leaflets?

Patient Information Leaflets (PILs) are created to translate the official, technical regulatory document into accessible language for the user. They focus on clearly explaining the drug’s role, known side effects, and important eligibility restrictions in a format that is concise and easy to read.

Storage and Disposal of Нитроксолин-УБФ (Nitroxoline)

Official regulatory guidelines define specific conditions for storing and disposing of this medicine to ensure stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically not exceeding 25 C.
Protection	Keep in the original container, tightly closed, in a cool, dry, and well-ventilated place.
Security	The medicine must be kept out of the sight and reach of children and stored in a locked location.

Disposal Instructions

Unused or expired tablets must be disposed of in accordance with local/national regulations for pharmaceutical waste. The product should not be disposed of via wastewater or flushed down the toilet. The preferred method is using a community drug take-back program or mail-back service when available.